Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2014

Open Access 01-02-2014 | Commentary

Predicting outcome in patients with sepsis: new biomarkers for old expectations

Authors: Pierre-Emmanuel Charles, Sébastien Gibot

Published in: Critical Care | Issue 1/2014

Login to get access

Abstract

Early prediction of the outcome of patients with sepsis could be helpful in guiding therapies but remains challenging. Presepsin, a new sepsis biomarker whose elevation as early as day 1 is well correlated with 28-day mortality, could be considered to this end.
Literature
1.
Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, Fumagalli R, Mauri T, Isgro S, Fanizza C, Romero M, Tognoni G, Latini R, Gattinoni L: Presepsin (soluble CD14 subtype, sCD14-ST) and procalcitonin for early mortality prediction in severe sepsis and septic shock. A retrospective case–control study from the Albumin Italian Outcome Sepsis (ALBIOS) trial. Crit Care 2014, 18: R6. 10.1186/cc13183PubMedCentralCrossRefPubMed
2.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39: 165-228. 10.1007/s00134-012-2769-8CrossRefPubMed
3.
Munford RS, Pugin J: Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001, 163: 316-321. 10.1164/ajrccm.163.2.2007102CrossRefPubMed
4.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9CrossRefPubMed
5.
Charles PE, Tinel C, Barbar S, Aho S, Prin S, Doise JM, Olsson NO, Blettery B, Quenot JP: Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009, 13: R38. 10.1186/cc7751PubMedCentralCrossRefPubMed
6.
Gibot S, Béné MC, Noel R, Massin F, Guy J, Cravoisy A, Barraud D, De Carvalho Bittencourt M, Quenot JP, Bollaert PE, Faure G, Charles PE: Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012, 186: 65-71. 10.1164/rccm.201201-0037OCCrossRefPubMed
7.
Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, Morello F, Lupia E, Moiraghi C, Mengozzi G, Battista S: Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care 2013, 17: R168. 10.1186/cc12847PubMedCentralCrossRefPubMed
8.
Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M, PRORATA trial group: Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375: 463-474. 10.1016/S0140-6736(09)61879-1CrossRefPubMed
9.
Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen AØ, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjær J, Grarup J, Lundgren JD, Procalcitonin And Survival Study (PASS) Group: Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011, 39: 2048-2058. 10.1097/CCM.0b013e31821e8791CrossRefPubMed
Metadata
Title
Predicting outcome in patients with sepsis: new biomarkers for old expectations
Authors
Pierre-Emmanuel Charles
Sébastien Gibot
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13723

Other articles of this Issue 1/2014

Critical Care 1/2014 Go to the issue

Research

Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study

Research

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

Research

Application of heart-rate variability in patients undergoing weaning from mechanical ventilation

Letter

Circulating neutrophil counts and mortality in septic shock

Review

Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults

Letter

Colistin dosing for treatment of multidrug-resistant Pseudomonasin critically ill patients - please, be adequate!